The WACC of Xvivo Perfusion AB (XVIVO.ST) is 7.3%.
| Range | Selected | |
| Cost of equity | 5.40% - 9.30% | 7.35% |
| Tax rate | 16.00% - 19.40% | 17.70% |
| Cost of debt | 5.00% - 5.00% | 5.00% |
| WACC | 5.4% - 9.3% | 7.3% |
| Category | Low | High |
| Long-term bond rate | 2.5% | 3.0% |
| Equity market risk premium | 5.1% | 6.1% |
| Adjusted beta | 0.36 | 0.79 |
| Additional risk adjustments | 1.0% | 1.5% |
| Cost of equity | 5.40% | 9.30% |
| Tax rate | 16.00% | 19.40% |
| Debt/Equity ratio | 0 | 0 |
| Cost of debt | 5.00% | 5.00% |
| After-tax WACC | 5.4% | 9.3% |
| Selected WACC | 7.3% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for XVIVO.ST:
cost_of_equity (7.35%) = risk_free_rate (2.75%) + equity_risk_premium (5.60%) * adjusted_beta (0.36) + risk_adjustments (1.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.